SCAI 2026 Workshop on the Treatment of Pulmonary Embolism-Panel Discussion 3

Video Transcription

Video Summary

The discussion focused on pulmonary embolism (PE) trials, risk stratification, and follow-up care. Speakers compared upcoming studies and suggested HiPITE may be the most “positive” trial because it uses a highly enriched population and a sensitive definition of clinical deterioration. PEERLESS2 may overcome less sensitive endpoints by using a larger sample, while P-TRACT is broader and more hypothesis-generating.<br /><br />The panel emphasized the need to ask better research questions: Are current data elements sufficient? Should PE-specific risk scores be developed instead of using generic tools like NEWS? They also highlighted the importance of functional outcomes, quality-of-life measures, lactate, hemodynamics, and possibly AI/CT perfusion in future studies.<br /><br />A major takeaway was the need for specialized long-term follow-up of PE patients, similar to post-MI care.

Asset Caption

closed captions are computer-generated

Keywords

pulmonary embolism

risk stratification

clinical trials

follow-up care

quality of life